AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT00875888 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: continuous venovenous hemodialysis
Description: dialysate flow rate 35 ml/h/kg. Blood flow rate should be aimed at 200 ml/min, but not less than 150 ml/min. Bicarbonate- or lactate-buffered solutions will be used as dialysis fluids. Study dialyzers will be changed routinely every 24 h or earlier if the filter is obstructed by clotting.
Study NCT04251858 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Dental Scaling
Description: The individuals will be treated by a single periodontist and the scaling and root planing procedures will be performed on all teeth as follows: local anesthetic infiltrative type of the areas to be treated, dental and root scaling using Grace 5/6 carbon steel curettes, 11/12, 13/14 and MacCall 13/14, 17/18 curettes, according to their therapeutic indications. Polishing the quadrants treated with abrasive paste; oral hygiene instructions including Bass toothbrushing, dental floss and sometimes inter-dental brush.
Study NCT04251858 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Oral hygiene instruction
Description: Oral hygiene instructions should be given to all study participants. Guidance on the most appropriate toothbrush, toothpaste and interproximal cleaning method.
Study NCT00781690 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Evodial hemodialysers and Evodia blood lines
Description: Maximum 8 weeks treatment with Evodial dialysers with reduction of heparin dose
Study NCT01949909 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CH-Alum50
Description: intramuscular administration to Swiss volunteers of Alhydrogel and P27A antigen (50 microg)
Study NCT00114101 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Melphalan
Description: Given IV
Study NCT00114101 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Melphalan
Description: Given IV
Study NCT00114101 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Peripheral Blood Stem Cell Transplantation
Description: Undergo autologous PBSCT
Study NCT00114101 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Peripheral Blood Stem Cell Transplantation
Description: Undergo autologous PBSCT
Study NCT00114101 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Administration
Description: Given PO
Study NCT01636817 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NNC0109-0012
Description: Administered subcutaneously (s.c., under the skin) once weekly.
Study NCT01949909 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CH-GLA2.5/50
Description: intramuscular administration to Swiss volunteers of GLA-SE (2.5microg) together with the P27A antigen (50 microg)
Study NCT01604408 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered SC
Study NCT01636817 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Administered subcutaneously (s.c., under the skin) once weekly.
Study NCT04755673 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Atrantil (Medical Food)
Description: All participants will be given 28 days supply of Atrantil. The impact of the intervention will be measured by daily symptom surveys as well as a hydrogen methane breath test administered at the end of the 28 days of treatment to identify if methane levels have changed.
Study NCT00877617 — intervention group
Intervention type: BEHAVIORAL
Intervention: QOL Questionnaire
Description: Mailed survey.
Study NCT03513536 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Citrus-Based Aromatherapy
Description: This intervention is a blend of plant derived oils which have been distilled from crude plant matter and analyzed in a laboratory to identify chemical composition.
Study NCT03513536 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mint-Based Aromatherapy
Description: This intervention is a blend of plant derived oils which have been distilled from crude plant matter and analyzed in a laboratory to identify chemical composition.
Study NCT03513536 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Spice-Scented Aromatherapy
Description: This intervention is a blend of plant derived oils which have been distilled from crude plant matter and analyzed in a laboratory to identify chemical composition.
Study NCT03513536 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Control
Description: This control is a blend of plant derived oils which have been expressed from crude plant matter.
Study NCT01100450 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Progressive Resistance Training
Description: 12-week progressive resistance training (PRT) exercise program
Study NCT00496028 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD0530
Description: oral tablet
Study NCT01949909 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: TZ Ver
Description: intramuscular administration of Rabies vaccine Verorub TM to in Phase IIb only to 8 Tanzanian volunteers in three injections
Study NCT01949909 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: TZ Alum 50
Description: intramuscular administration to Tanzanian volunteers of Alhydrogel and P27A antigen (50 microg)
Study NCT04035135 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ANX005
Description: investigational drug
Study NCT04035135 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intravenous immunoglobulin
Description: investigational drug
Study NCT01949909 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: TZ GLA 2.5/10
Description: intramuscular administration to Tanzanian volunteers of GLA-SE (2.5 microg ) together with the P27A antigen (10 microg)
Study NCT01949909 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: TZ GLA5/50
Description: intramuscular administration to Tanzanian volunteers of GLA-SE (5 microg) together with the P27A antigen (50 microg)
Study NCT05536583 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Laparoscopic sleeve Gastrectomy
Description: Laparoscopic sleeve Gastrectomy
Study NCT01949909 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: TZ GLA2.5/50
Description: intramuscular administration to Tanzanian volunteers of GLA-SE (2.5microg) together with the P27A antigen (50 microg)
Study NCT03086512 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Acutrak 2® - 7.5 Screw
Description: The Acumed Acutrak 2® - 7.5 is a fully-threaded headless screw fixation, composed of 17 unique screw size options. The Acutrak 2® - 7.5 is available in sizes from 40 mm to 120 mm and is inserted using a 4.0 mm hex driver over a .094 guide wire. The Acutrak 2 Part Number is 30-0XXX and 30-0XXX-S.
Study NCT03086512 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Synthes® 7.3 Cannulated Screw
Description: The Synthes® 7.3 mm Cannulated screws are available in three thread options: 16 mm, 32 mm or fully threaded. This study will use the partially threaded options. The screws can be placed by small diameter guide wires. They are composed of 316L stainless steel or titanium alloy (Ti-6Al-7Nb).
Study NCT05339971 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: block perforation
Description: The bone block used for lateral bone augmentation will be perforated several times.
Study NCT03931044 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Image-Guided Robotic Gastrectomy
Description: The near-infrared technology, integrated in the robotic camera, will be used to detect fluorescent lymphonodes.
Study NCT00930813 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Lutonix Catheter
Description: Paclitaxel Coated Balloon Catheter
Study NCT00930813 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Standard uncoated Balloon Angioplasty Catheter
Description: plain, uncoated angioplasty balloon catheter
Study NCT02013986 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: etomidate
Description: 0.3mg/kg IV only once during induction of general anesthesia
Study NCT02013986 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: midazolam
Description: midazolam 0.1mg/kg IV only once before using of etomidate/propofol during induction of general anesthesia
Study NCT02013986 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: midazolam
Description: midazolam 0.1mg/kg IV only once before using of etomidate/propofol during induction of general anesthesia
Study NCT02013986 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: propofol
Description: 2mg/kg IV only once during induction of general anesthesia
Study NCT03318536 — intervention group
Intervention type: DRUG
Intervention: Granisetron Hydrochloride
Description: Patients received Granisetron.
Study NCT03318536 — intervention group
Intervention type: DRUG
Intervention: No Granisetron
Description: Patients who did not receive Granisetron.
Study NCT01693614 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Buparlisib
Description: 100 mg hard gelatin capsules administered orally, once daily in cycles of 28 days
Study NCT01133132 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Survivorship CHESS
Description: Once the consent, baseline survey and one week accelerometer data is received by the UW research team subjects will be randomized to one of the two study conditions. Subjects will be notified of their randomization. Subjects randomized to the Survivorship CHESS condition will be offered training on the smartphone and the CHESS system. The project director (and site research coordinators) will provide training on the smartphone either in person or over the phone. Additionally, an online tutorial will be included in the Survivorship CHESS intervention for subjects to refer to as needed. Participants will then be asked to complete four surveys one baseline and then three follow up surveys.
Study NCT01133132 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Survivorship CHESS
Description: Once the consent, baseline survey and one week accelerometer data is received by the UW research team subjects will be randomized to one of the two study conditions. Subjects will be notified of their randomization. Subjects randomized to the Survivorship CHESS condition will be offered training on the smartphone and the CHESS system. The project director (and site research coordinators) will provide training on the smartphone either in person or over the phone. Additionally, an online tutorial will be included in the Survivorship CHESS intervention for subjects to refer to as needed. Participants will then be asked to complete four surveys one baseline and then three follow up surveys.
Study NCT01133132 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Control
Description: This person will receive usual care and a copy of the National Cancer Institute's Facing Forward booklet and the National Cancer Center Network cancer survivor toolbox.
Study NCT02082405 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bortezomib
Description: Given SC or IV
Study NCT02082405 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclophosphamide
Description: Given PO
Study NCT02082405 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dexamethasone
Description: Given PO
Study NCT02082405 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Optional correlative studies
Study NCT00496028 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: intravenous infusion
Study NCT00496028 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: intravenous infusion
Study NCT02082405 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: quality-of-life assessment
Description: Ancillary studies
Study NCT02485626 — intervention group
Intervention type: PROCEDURE
Intervention: 2D tissue doppler echocardiography
Study NCT01779388 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bronchoscopy
Description: During a general anaesthesia, an evaluation will be done by conventional bronchoscopy guided by fluoroscopy and by bronchial endoscopy guided by electromagnetic navigation, the selection of order in techniques being randomly assigned.
Study NCT01779388 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Bronchoscopy
Description: During a general anaesthesia, an evaluation will be done by conventional bronchoscopy guided by fluoroscopy and by bronchial endoscopy guided by electromagnetic navigation, the selection of order in techniques being randomly assigned.
Study NCT02480335 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bosentan
Description: 62.5 mg oral twice daily for 4 weeks, then 125 mg oral twice daily.
Study NCT02145182 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eculizumab
Description: Eculizumab is a complement component 5 inhibitor.
Study NCT02145182 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 0.9% sodium chloride
Study NCT03168191 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nicotine
Description: Participants will receive low dose nicotine (6 mg/ml) or high dose nicotine (12 mg/ml)
Study NCT03168191 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Nicotine
Description: Participants will receive low dose nicotine (6 mg/ml) or high dose nicotine (12 mg/ml)
Study NCT03168191 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Experimental Flavor
Description: Experimental fruit flavored e-cigarette for lab session
Study NCT03168191 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Menthol Flavor
Description: Menthol flavored e-cigarette for lab session
Study NCT01360840 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EMD 525797
Description: Subjects will be administered with EMD 525797 at a dose of 1500 milligram (mg) (diluted with 0.9 percent \[%\] sodium chloride) as a 1-hour intravenous infusion every 3 Weeks until disease progression or unacceptable toxicity, whichever comes first, unless the subject stopped the trial treatment for other reasons.
Study NCT01360840 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EMD 525797
Description: Subjects will be administered with EMD 525797 at a dose of 750 mg (diluted with 0.9% sodium chloride) as a 1-hour intravenous infusion every 3 Weeks until disease progression or unacceptable toxicity, whichever comes first, unless the subject stopped the trial treatment for other reasons.
Study NCT01360840 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Subjects will be administered with placebo (as 0.9% sodium chloride) as a 1-hour intravenous infusion every 3 Weeks until disease progression or unacceptable toxicity, whichever comes first, unless the subject stopped the trial treatment for other reasons.
Study NCT01360840 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard of Care (SoC)
Description: All the subjects followed the SoC consisting of the continued treatment with luteinizing-hormone releasing hormone agonists (or antagonists).
Study NCT02023840 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: metronidazole gel
Study NCT02023840 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: ultrasonics
Study NCT02023840 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: ultrasonics
Study NCT02023840 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: erythritol
Study NCT02023840 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: erythritol
Study NCT02023840 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Study NCT04299776 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CirQPOD
Description: CirQPOD is connected between the wye piece on ventilator/anesthesia machine tubing and the patient's airway and generates negative intrathoracic pressure during the expiratory phase of ventilation which has been shown to improve blood flow.
Study NCT04299776 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Standard airway management
Description: Standard airway management during surgery (PEEP of +5 cmH2O)
Study NCT00784979 — intervention group
Intervention type: DRUG
Group type: NO_INTERVENTION
Intervention: CMVIG
Description: 400mg/kg IV (60mg/kg/IV/hr initially, titrated up) once a week up to four weeks
Study NCT02343965 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Touch-massage
Study NCT04080596 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dorzagliatin
Description: GKA for T2DM currently under clinical development
Study NCT03209609 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: VEST
Description: External support for vein grafts, cobalt chrome braid
Study NCT03209609 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Coronary artery bypass vein grafts
Description: Bypass coronary arteries with autologous saphenous vein grafts
Study NCT03209609 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Coronary artery bypass vein grafts
Description: Bypass coronary arteries with autologous saphenous vein grafts
Study NCT01958515 — intervention group
Intervention type: OTHER
Intervention: research blood draw and tissue biopsy
Description: research blood draw and tissue biopsy
Study NCT02997878 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Orbcel-C
Description: Selected Mesenchymal Stromal Cells derived from human umbilical cord
Study NCT04867811 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: conventional therapy
Description: conventional therapy
Study NCT04867811 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: cupping therapy
Description: cupping therapy
Study NCT04867811 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: TENS
Description: transcutaneous electrical nerve stimulation
Study NCT04867811 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: TENS and cupping therapy
Description: TENS and cupping therapy
Study NCT02218307 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mupirocin
Study NCT02218307 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT00934557 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ATG Fresenius
Study NCT05536583 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Laparoscopic sleeve Gastrectomy
Description: Laparoscopic sleeve Gastrectomy
Study NCT01360840 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Standard of Care (SoC)
Description: All the subjects followed the SoC consisting of the continued treatment with luteinizing-hormone releasing hormone agonists (or antagonists).
Study NCT00016913 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: carboplatin
Description: AUC=6 week one of each 4 week cycle
Study NCT00016913 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: estramustine
Description: 2 tablets tid PO 5 of 7 days per week each 4 week cycle
Study NCT00016913 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: paclitaxel
Description: 80 mg/sq m IV infusion over 1 hour weekly for ea 4 week cycle
Study NCT00016913 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: radiation therapy
Description: 77.4 Gy in 1.8 Gy fractions
Study NCT00016913 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: leuprolide or goserelin acetate
Description: 7.5 mg IM injection once every 4 weeks for 6 months
Study NCT04521192 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluzoparib
Description: the first period: test preparation; the second period: reference preparation
Study NCT04521192 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluzoparib
Description: the first period: reference preparation the second period: test preparation
Study NCT03999554 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: LD Sing2016 M2SR H3N2 influenza vaccine
Description: This group will receive a low dose of the Sing2016 M2SR H3N2 monovalent influenza vaccine administered intranasally.
Study NCT03999554 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MD Sing2016 M2SR H3N2 influenza vaccine
Description: This group will receive a medium dose of the Sing2016 M2SR H3N2 monovalent influenza vaccine administered intranasally.
Study NCT03999554 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: HD Sing2016 M2SR H3N2 influenza vaccine
Description: This group will receive a high dose of the Sing2016 M2SR H3N2 monovalent influenza vaccine administered intranasally.
Study NCT00075218 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 50 mg taken orally once a day. 6 week treatment cycle (Schedule 4/2) 4 weeks on study drug/2 weeks off study drug.
Study NCT00075218 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: SU011248
Description: 50 mg taken orally once a day. 6 week treatment cycle (Schedule 4/2) 4 weeks on study drug/2 weeks off study drug.
Study NCT04198428 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Opioid Wizard
Description: The Opioid Wizard is an OUD clinical decision support tool for primary care providers to help assess, diagnose, and treat OUD in primary care (where appropriate).